Duke tests new combo to shield patients after High-Risk cancer transplant
NCT ID NCT06731504
Summary
This early-stage study is testing whether a three-drug combination is safe and practical for preventing graft-versus-host disease (GVHD) after a specific type of stem cell transplant for blood cancers. The transplant uses specially processed cord blood cells. Researchers will enroll about 10 adult patients with blood cancers to monitor them closely for side effects and see if the drug regimen can be successfully given.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Health System
RECRUITINGDurham, North Carolina, 27705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.